Phenotypes associated with this allele

• Allele Symbol: Tg(GFAP-tTA)110Pop
• Allele Name: transgene insertion 110, Brian Popko
• Allele ID: MGI:3702613
• Summary: 4 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cx1	Tg(GFAP-tTA)110Pop/0 Tg(tetO-DISC1*)1302BPlet/0	B6.Cg-Tg(GFAP-tTA)110Pop Tg(tetO-DISC1*)1302BPlet	MGI:6287130
cx2	Eif2ak3^tm1Dron/Eif2ak3^tm1Dron Tg(GFAP-tTA)110Pop/0 Tg(tetO-Ifng)184Pop/0	involves: 129S6/SvEvTac * C57BL/6 * DBA/2 * Swiss Webster	MGI:4355948
cx3	Eif2ak3^tm1Dron/Eif2ak3^+ Tg(GFAP-tTA)110Pop/0 Tg(tetO-Ifng)184Pop/0	involves: 129S6/SvEvTac * C57BL/6 * DBA/2 * Swiss Webster	MGI:4355950
cx4	Tg(GFAP-tTA)110Pop/0 Tg(tetO-Ifng)184Pop/0	involves: 129S6/SvEvTac * C57BL/6 * DBA/2 * Swiss Webster	MGI:4355952

Genotype
MGI:6287130

cx1

• Allelic Composition: Tg(GFAP-tTA)110Pop/0; Tg(tetO-DISC1*)1302BPlet/0
• Genetic Background: B6.Cg-Tg(GFAP-tTA)110Pop Tg(tetO-DISC1*)1302BPlet

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

homeostasis/metabolism

abnormal serine level ( J:244437 )

• a modest 20% decrease in forebrain levels of D-serine in newborn mice, with no differences at P7, a slight increase at P21 and no differences at P90

decreased serine level ( J:244437 )

• mice exhibit an approximate 45% decrease in generation of D-serine from L-serine

behavior/neurological

behavior/neurological phenotype ( J:244437 )

N • no differences from controls are seen in anxiety in the elevated plus maze, spontaneous alternations, or special recognition memory in the Y maze

enhanced behavioral response to xenobiotic ( J:244437 )

• mice treated with an NMDA antagonist MK-801 show greater locomotor stimulation and a greater disruption in pre-pulse inhibition at intensities of pre-pulses of 4 dB and 8 dB than controls

• supplementation with D-serine of MK-801 treated mice reduces hyperactivity of mutants more than wild-type mice and increases the reduction of pre-pulse inhibition indicating increased sensitivity to the effects of D-serine

increased locomotor activity ( J:244437 )

• mice treated with an NMDA antagonist MK-801 show greater locomotor stimulation than control mice

• supplementation with D-serine of MK-801 treated mice reduces hyperactivity of mutants more than wild-type mice

nervous system

nervous system phenotype ( J:244437 )

N • mice show no gross defects in cytoarchitecture and layer of the hippocampus or cerebellum

decreased prepulse inhibition ( J:244437 )

• mice treated with MK-801 show a greater disruption in pre-pulse inhibition at intensities of pre-pulses of 4 dB and 8 dB than controls

• supplementation with D-serine of MK-801 treated mice increases the reduction of pre-pulse inhibition

Genotype
MGI:4355948

cx2

• Allelic Composition: Eif2ak3^tm1Dron/Eif2ak3^tm1Dron; Tg(GFAP-tTA)110Pop/0; Tg(tetO-Ifng)184Pop/0
• Genetic Background: involves: 129S6/SvEvTac * C57BL/6 * DBA/2 * Swiss Webster

mortality/aging

postnatal lethality, complete penetrance ( J:99655 )

• pups die around P12 regardless whether dams received doxycycline to the end of gestation or until E14

Genotype
MGI:4355950

cx3

• Allelic Composition: Eif2ak3^tm1Dron/Eif2ak3⁺; Tg(GFAP-tTA)110Pop/0; Tg(tetO-Ifng)184Pop/0
• Genetic Background: involves: 129S6/SvEvTac * C57BL/6 * DBA/2 * Swiss Webster

mortality/aging

premature death ( J:99655 )

• greater than 90% of animals die by postnatal day 27

growth/size/body

postnatal growth retardation ( J:99655 )

• pups are significantly smaller than controls littermates when doxycycline treatment is stopped on E14

nervous system

tonic seizures ( J:99655 )

• >60% of animals display tonic seizures

abnormal oligodendrocyte apoptosis ( J:99655 )

• in cervical spinal cord at P14, number of apoptotic oligodendrocytes is significantly greater than in controls when doxycycline treatment is stopped at E14

increased spinal cord apoptosis ( J:99655 )

• in cervical spinal cord at P14, number of apoptotic oligodendrocytes is significantly greater than in controls when doxycycline treatment is stopped at E14

abnormal oligodendrocyte morphology ( J:99655 )

• when doxycycline treatment is stopped at E14, very few oligodendrocytes are detected in corpus callosum and cerebellum at P14

• if mice are treated with doxycycline until they reach maturity (4 weeks) and then are released from doxycycline, oligodendrocyte survival is unaffected

abnormal spinal cord white matter morphology ( J:99655 )

• >80% of axons are unmyelinated compared to 30% of spinal cord axons in double mutants on a wild-type Eif2ak3 background when doxycycline treatment is stopped at E14; in mice continuously receiving doxycycline treatment, <10% of spinal cord axons are unmyelinated

• if mice are treated with doxycycline until they reach maturity (4 weeks) and then are released from doxycycline, normal myelin is observed in the central nervous system

abnormal myelination ( J:99655 )

• level of myelin in CNS is significantly reduced at P14 compared to double transgenic mice with wild-type Eif2ak3

behavior/neurological

tremors ( J:99655 )

• severe tremors are observed

tonic seizures ( J:99655 )

• >60% of animals display tonic seizures

cellular

abnormal oligodendrocyte apoptosis ( J:99655 )

• in cervical spinal cord at P14, number of apoptotic oligodendrocytes is significantly greater than in controls when doxycycline treatment is stopped at E14

increased spinal cord apoptosis ( J:99655 )

• in cervical spinal cord at P14, number of apoptotic oligodendrocytes is significantly greater than in controls when doxycycline treatment is stopped at E14

Genotype
MGI:4355952

cx4

• Allelic Composition: Tg(GFAP-tTA)110Pop/0; Tg(tetO-Ifng)184Pop/0
• Genetic Background: involves: 129S6/SvEvTac * C57BL/6 * DBA/2 * Swiss Webster

mortality/aging

mortality/aging ( J:99655 )

N • when doxycycline treatment is stopped at E14, double transgenic offspring exhibit good survival

behavior/neurological

tremors ( J:99655 )

• pups exhibit minor tremor

ataxia ( J:99655 )

• pups exhibit minor ataxia